179 related articles for article (PubMed ID: 28927685)
1. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
[TBL] [Abstract][Full Text] [Related]
2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
3. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
[TBL] [Abstract][Full Text] [Related]
8. Kawasaki disease: part II. Complications and treatment.
Bayers S; Shulman ST; Paller AS
J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Yang X; Liu G; Huang Y; Chen S; Du J; Jin H
Cardiol Young; 2015 Aug; 25(6):1182-90. PubMed ID: 25597708
[TBL] [Abstract][Full Text] [Related]
10. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
J Am Heart Assoc; 2020 Sep; 9(17):e015308. PubMed ID: 32811256
[TBL] [Abstract][Full Text] [Related]
12. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G; Gale S; Ponniah T
Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
15. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
Zheng X; Li J; Yue P; Liu L; Li J; Zhou K; Hua Y; Li Y
PLoS One; 2021; 16(3):e0248812. PubMed ID: 33764989
[TBL] [Abstract][Full Text] [Related]
16. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.
Lin MT; Sun LC; Wu ET; Wang JK; Lue HC; Wu MH
Arch Dis Child; 2015 Jun; 100(6):542-7. PubMed ID: 25564534
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study.
Wang Z; Weng F; Li C; Shi H; Tang Z; Qiu H; He Y; Wu R; Chu M
BMC Pediatr; 2018 Feb; 18(1):76. PubMed ID: 29466965
[TBL] [Abstract][Full Text] [Related]
18. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease.
Kijima Y; Kamiya T; Suzuki A; Hirose O; Manabe H
Jpn Circ J; 1982 Nov; 46(11):1239-42. PubMed ID: 7131714
[TBL] [Abstract][Full Text] [Related]
19. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
Michihata N; Matsui H; Fushimi K; Yasunaga H
Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
[TBL] [Abstract][Full Text] [Related]
20. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
